[go: up one dir, main page]

WO2010127152A3 - Compounds and compositions as microsomal prostaglandin e synthase-1 inhibitors - Google Patents

Compounds and compositions as microsomal prostaglandin e synthase-1 inhibitors Download PDF

Info

Publication number
WO2010127152A3
WO2010127152A3 PCT/US2010/033022 US2010033022W WO2010127152A3 WO 2010127152 A3 WO2010127152 A3 WO 2010127152A3 US 2010033022 W US2010033022 W US 2010033022W WO 2010127152 A3 WO2010127152 A3 WO 2010127152A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
inhibitors
compositions
synthase
microsomal prostaglandin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/033022
Other languages
French (fr)
Other versions
WO2010127152A2 (en
Inventor
Donatella Chianelli
Valentina Molteni
Pamela A. Albaugh
Ha-Soon Choi
Jon Loren
Zhicheng Wang
Pranab Mishra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IRM LLC
Original Assignee
IRM LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IRM LLC filed Critical IRM LLC
Publication of WO2010127152A2 publication Critical patent/WO2010127152A2/en
Publication of WO2010127152A3 publication Critical patent/WO2010127152A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Provided herein are compounds, and pharmaceutical compositions comprising such compounds, wherein the compounds are inhibitors of mPGES-1 activity. Also provided herein are methods of using such compounds and composition to treat or prevent diseases or disorders associated with the activity of mPGES-1.
PCT/US2010/033022 2009-04-29 2010-04-29 Compounds and compositions as microsomal prostaglandin e synthase-1 inhibitors Ceased WO2010127152A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17379509P 2009-04-29 2009-04-29
US61/173,795 2009-04-29

Publications (2)

Publication Number Publication Date
WO2010127152A2 WO2010127152A2 (en) 2010-11-04
WO2010127152A3 true WO2010127152A3 (en) 2011-09-29

Family

ID=42272690

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/033022 Ceased WO2010127152A2 (en) 2009-04-29 2010-04-29 Compounds and compositions as microsomal prostaglandin e synthase-1 inhibitors

Country Status (1)

Country Link
WO (1) WO2010127152A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
ES2620027T3 (en) 2008-09-03 2017-06-27 Biomarin Pharmaceutical Inc. Compositions that include 6-aminohexanoic acid derivatives as HDAC inhibitors
JP2013516480A (en) 2010-01-07 2013-05-13 セレクサゲン セラピューティクス，インク． Hedgehog inhibitor
EP2552208A4 (en) * 2010-03-31 2014-07-09 Glaxo Group Ltd Imidazolyl-imidazoles as kinase inhibitors
AR084174A1 (en) * 2010-12-21 2013-04-24 Lilly Co Eli IMIDAZOL-2-BENZAMIDA COMPOUNDS USEFUL FOR THE TREATMENT OF OSTEOARTRITIS AND A PHARMACEUTICAL COMPOSITION
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US9540395B2 (en) 2011-02-28 2017-01-10 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
AR086254A1 (en) * 2011-05-26 2013-11-27 Lilly Co Eli USEFUL IMIDAZOL DERIVATIVES FOR THE TREATMENT OF ARTHRITIS
US20130165472A1 (en) * 2011-12-23 2013-06-27 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
WO2013170774A1 (en) * 2012-05-16 2013-11-21 上海医药集团股份有限公司 Acetylene derivative having antineoplastic activity
JP2015525223A (en) 2012-06-14 2015-09-03 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ Pest control method using substituted 3-pyridylthiazole compounds and derivatives for controlling animal pests
JP6387391B2 (en) 2013-03-14 2018-09-05 ノバルティス アーゲー 2- (1H-Indol-4-ylmethyl) -3H-imidazo [4,5-b] pyridine-6-carbonitrile derivatives as complement factor B inhibitors useful for the treatment of ophthalmic diseases
KR20150132345A (en) 2013-03-15 2015-11-25 바이오마린 파머수티컬 인크. Hdac inhibitors
EP3089963A1 (en) 2013-10-30 2016-11-09 Novartis AG 2-benzyl-benzimidazole complement factor b inhibitors and uses thereof
CN105899504A (en) * 2014-01-21 2016-08-24 豪夫迈·罗氏有限公司 Imidazoles for the treatment and prophylaxis of respiratory syncytial virus infection
CA3079483A1 (en) 2017-11-22 2019-05-31 Khondrion Ip B.V. Compounds as mpges-1 inhibitors
JP2025527659A (en) * 2022-08-24 2025-08-22 インシリコ メディシン アイピー リミテッド Method for producing kinase inhibitors
WO2025007950A1 (en) * 2023-07-06 2025-01-09 Insilico Medicine Ip Limited Crystalline tnik inhibitor and uses thereof
WO2025151705A1 (en) * 2024-01-10 2025-07-17 Vrise Therapeutics, Inc. Novel inhibitors of dna damage repair pathway

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005123673A1 (en) * 2004-06-18 2005-12-29 Biolipox Ab Indoles useful in the treatment of inflammation
US20070208017A1 (en) * 2004-12-17 2007-09-06 Anh Chau 2-(Phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
WO2008084218A1 (en) * 2007-01-12 2008-07-17 Boehringer Ingelheim International Gmbh Benzazole derivatives for the treatment of inflammations
WO2008139161A1 (en) * 2007-05-10 2008-11-20 Sareum Limited Oxazole tyrosine kinase inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005123673A1 (en) * 2004-06-18 2005-12-29 Biolipox Ab Indoles useful in the treatment of inflammation
US20070208017A1 (en) * 2004-12-17 2007-09-06 Anh Chau 2-(Phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
WO2008084218A1 (en) * 2007-01-12 2008-07-17 Boehringer Ingelheim International Gmbh Benzazole derivatives for the treatment of inflammations
WO2008139161A1 (en) * 2007-05-10 2008-11-20 Sareum Limited Oxazole tyrosine kinase inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ST. LAURANT DR ET AL: "Preparation of 5-substituted 2-(2-alkyl/aryl-1H-imidazol-4-yl)oxazoles and 5-substituted 2-(2-alkyl/arylthiazol-4-yl)oxazoles by utilizing 5-substituted 2-(2-bromo-1,1-diethoxyethyl)oxazole as a synthon", SYNTHESIS, no. 9, 25 March 2009 (2009-03-25), pages 1445 - 1458, XP002589898 *
TANAKA ET AL: "Studies on antiplatelet agents i. Synthesis and platelet inhibitory activity of 5-alkyl-2-aryl-4-pyridylimidazoles", CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 40, no. 12, 1 January 1992 (1992-01-01), pages 3206 - 3213, XP002651273 *

Also Published As

Publication number Publication date
WO2010127152A2 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
WO2010127152A3 (en) Compounds and compositions as microsomal prostaglandin e synthase-1 inhibitors
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
MX2009009491A (en) Compounds and compositions as modulators of gpr119 activity.
MX2009007944A (en) Compounds and compositions as kinase inhibitors.
WO2011014795A3 (en) Compounds and compositions as syk kinase inhibitors
MX2012004078A (en) Compounds and compositions as modulators of gpr119 activity.
WO2009089494A3 (en) Pharmaceutical compositions
WO2008118332A3 (en) Hydrazido-peptides as inhibitors of hcv ns3-protease
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
EA200901032A1 (en) COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS
WO2010083207A3 (en) Protein kinase c inhibitors and uses thereof
EA201100138A1 (en) 4-PHENOXYMETHYL-PIPERIDINES AS MODEL ACTIVITY GPR119
WO2009129246A3 (en) Compositions and methods for preparing and using same
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
EA026892B9 (en) TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS
WO2012125544A3 (en) Necroptosis inhibitors and methods of use therefor
WO2008033562A3 (en) Kinase inhibitor compounds
UA103930C2 (en) Normal;heading 1;heading 2;heading 3;COMPOUNDS AND COMPOSITION FOR THE TREATMENT OF PARASITIC DISEASES
IN2012DN03182A (en)
WO2008070268A3 (en) Pharmaceutical compositions
WO2007125105A3 (en) Benzamide glucokinase activators
WO2010147830A3 (en) Aminothiazole modulators of beta-3-adrenoreceptor
HK1251566A1 (en) Piperidine derivatives as hdac1/2 inhibitors
WO2011088160A3 (en) Novel cyp17 inhibitors
WO2010062506A3 (en) Decahydro-1h-indenoquinolinone and decahydro-3h-cyclopentaphenanthridinone cyp17 inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10717391

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10717391

Country of ref document: EP

Kind code of ref document: A2